2,8-Dihydroxyadenine (2,8-DHA) Urolithiasis

2,8-dihydroxyadenine (DHA) urolithiasis is a rare form of kidney stone disease. It happens when the body cannot recycle the purine base adenine in the normal “salvage” pathway. The missing step is the enzyme adenine phosphoribosyltransferase (APRT). When APRT does not work, adenine is diverted to another pathway and is changed by xanthine oxidoreductase into 2,8-dihydroxyadenine. DHA is very poorly soluble in urine. It forms many tiny crystals that join together to make stones. These stones can block urine flow, inflame the kidney, and scar the tissue. Recurrent stones can lead to chronic kidney disease and even kidney failure if not treated. The condition is autosomal recessive, so both gene copies must be affected. People of any age can develop stones, from infants to adults. The disease is often missed because DHA stones are radiolucent on plain X-rays, and they can look like uric-acid stones unless special tests are used. Good treatment exists. Medicines that block xanthine oxidoreductase (such as allopurinol or febuxostat) stop DHA formation, prevent new stones, and protect kidney function. High fluid intake and a low-purine diet help, but medicine is the key.

2,8-dihydroxyadenine urolithiasis is a rare, inherited kidney stone disease. It happens when the body cannot recycle a natural molecule called adenine because of a missing or weak enzyme named adenine phosphoribosyltransferase (APRT). Without APRT, adenine is changed by another enzyme (xanthine oxidoreductase) into 2,8-dihydroxyadenine (2,8-DHA). 2,8-DHA does not dissolve well in urine, so it forms tiny crystals. These crystals can clump into stones in the kidneys or urinary tract and can also block kidney tubules and cause kidney inflammation and scarring. If the problem is not found and treated early, it can lead to chronic kidney disease or even kidney failure. The most effective medical treatment is a lifelong xanthine oxidoreductase inhibitor (such as allopurinol or febuxostat) plus high fluid intake and a low-purine diet to reduce adenine production. Even after a kidney transplant, the condition can come back if the enzyme problem is not treated. Lippincott JournalsAJKDNCBIPMC

Another names

This condition is also called APRT deficiency–related urolithiasis, 2,8-dihydroxyadenine nephrolithiasis, DHA crystalline nephropathy, adenine phosphoribosyltransferase deficiency, APRT deficiency, dihydroxyadenine stone disease, and hereditary 2,8-dihydroxyadeninuria. In kidney transplant patients it may be described as recurrent DHA crystalline nephropathy in the graft. In laboratory reports you may see 2,8-DHA crystals or dihydroxyadenine calculi. All these names point to the same root problem: lack of APRT activity leading to DHA build-up and kidney injury.

Types

1. By cause (primary vs. treatment-related): Almost all cases are primary, due to inherited APRT deficiency. Very rarely, short-term DHA crystalluria can occur if someone ingests large amounts of adenine or receives unusual adenine analog drugs, but this is exceptional.

2. By age of presentation: Pediatric-onset presents in infants or children with stones, hematuria, or kidney dysfunction. Adult-onset presents later, often after years of unrecognized stone episodes.

3. By main clinical picture: Stone-predominant disease causes renal colic and frequent stone passage. Crystalline nephropathy–predominant disease shows fewer stones but more kidney inflammation and scarring from widespread DHA crystals.

4. By kidney status: Native-kidney disease happens before any transplant. Post-transplant recurrence happens when the inherited enzyme defect is not diagnosed and DHA crystals injure the new kidney.

5. By severity: Mild disease has occasional stones and normal kidney function. Moderate disease shows frequent stones and early loss of filtration. Severe disease has repeated obstruction, infections, and chronic kidney disease.

6. By laterality: Unilateral stones affect one side at a time. Bilateral disease affects both kidneys and raises the risk of acute blockage and kidney failure.

7. By control status: Well-controlled disease shows no new stones after starting allopurinol/febuxostat and high fluids. Uncontrolled disease has ongoing stones, often due to late diagnosis, poor adherence, or under-dosing.

8. By genetic background: APRT type I (common in many populations) usually means near-absent enzyme activity; APRT type II (reported more in some Japanese kindreds) may show residual activity in some tissues but still causes DHA overproduction.

Causes

1. Autosomal recessive APRT deficiency: The core cause. Both gene copies are changed, so APRT enzyme cannot convert adenine to AMP. Adenine is then turned into 2,8-DHA, which crystallizes in urine.

2. High purine intake: Eating many purine-rich foods (organ meats, some fish, game) raises adenine production. In APRT deficiency this extra adenine becomes more DHA, aggravating stones.

3. Low urine volume (dehydration): Not drinking enough water, heavy sweating, fever, or hot climates make urine concentrated. Concentrated urine promotes DHA crystal formation and growth.

4. Acidic urine: DHA is poorly soluble over a wide pH range, but acidic urine further reduces solubility. This favors crystal aggregation and stone growth.

5. Frequent urinary tract infections: Inflammation and debris in the urinary tract can act as a “scaffold” for DHA crystals to stick and build stones.

6. Urinary stasis or obstruction: Narrowing at the ureter or ureteropelvic junction slows flow. Slow flow gives crystals more time to join and form larger stones.

7. Early life transitions (weaning, illness): Babies or children with low fluid intake during weaning or illness can form crystals rapidly due to low urine volume.

8. Poor adherence to XO-inhibitors: Skipping or stopping allopurinol or febuxostat removes the metabolic block, so DHA production resumes and stones recur.

9. Under-dosed XO-inhibitors: If the dose is too low for body size or kidney function, the enzyme block is incomplete and crystals may still form.

10. Delayed diagnosis: Years of untreated disease allow many crystals to deposit in kidney tissue, causing scarring and reduced filtration.

11. Post-transplant unrecognized APRT deficiency: If donors or recipients are not evaluated for APRT deficiency, DHA crystals can recur in the new kidney and damage the graft.

12. Low urine citrate: Citrate is a natural inhibitor of crystal aggregation. Low levels remove this protection and favor stone growth.

13. High urinary uric acid from diet: While DHA is distinct from uric acid, high uric acid can acidify urine and reduce inhibitors, indirectly aiding DHA crystallization.

14. Genetic variants that reduce residual APRT activity: Some mutations leave tiny enzyme activity that still is not enough to prevent DHA build-up, especially under stress.

15. Intercurrent febrile illnesses: Fever and tachypnea cause insensible fluid loss and lower urine volume, encouraging crystal formation.

16. Pregnancy-related low fluid intake or vomiting: Volume depletion and acid-base shifts may increase crystal risk if APRT deficiency is present.

17. High-protein crash diets: Sudden high purine load plus low fluid intake can push adenine toward DHA formation.

18. Medications that reduce urine volume: Some diuretics or anticholinergics can lead to relative dehydration and concentrated urine.

19. Chronic diarrhea: Ongoing fluid losses reduce urine volume and increase urinary acidity, both of which favor crystal formation.

20. Missed family screening: If one child is diagnosed but siblings are not tested, another affected child may remain untreated and develop the disease.

Symptoms

1. Renal colic: Sharp, cramping flank pain due to a stone moving in the ureter. Pain can come in waves and may radiate to the groin.

2. Gross or microscopic hematuria: Blood in urine makes it pink, red, or tea-colored. Sometimes blood is only seen under the microscope.

3. Dysuria: Burning or pain during urination when crystals irritate the lining of the urinary tract.

4. Urinary frequency and urgency: The bladder feels irritated by crystals or small stones, leading to frequent small voids.

5. Passage of sandy or brownish crystals: Patients may notice fine, brown “sand” or tiny spheres in urine. This is DHA crystalluria.

6. Nausea and vomiting: Severe colic or obstruction can trigger vomiting and poor oral intake, which worsens dehydration.

7. Fever and chills (with infection): A blocked infected kidney can cause fever. This is an emergency.

8. Flank or back tenderness: The area over the kidney is sore to touch, especially during acute obstruction.

9. Oliguria or anuria: Very low urine output or no urine suggests severe obstruction or advanced kidney injury.

10. Fatigue: Chronic kidney disease reduces energy due to anemia and toxin build-up.

11. Swelling of legs or face: Salt and water retention occur as kidney function worsens.

12. High blood pressure: Kidney scarring and sodium retention raise blood pressure.

13. Poor growth in children: Recurrent stones and kidney disease can limit growth and weight gain.

14. Foamy urine: Protein leakage from damaged filters may make urine look foamy.

15. Graft dysfunction after transplant: Rising creatinine and low urine output in a transplanted kidney can signal recurrent DHA crystal injury.

Diagnostic tests

(organized by Physical Exam, Manual tests, Lab/Pathological, Electrodiagnostic, and Imaging. Each test includes what it is and why it helps.)

Physical exam

1. Vital signs check: Temperature, pulse, and blood pressure give quick clues. Fever suggests infection; high blood pressure suggests chronic kidney damage.

2. Hydration status: Dry mouth, low skin turgor, and orthostatic dizziness point to dehydration. Dehydration concentrates urine and promotes crystal formation.

3. Abdominal and flank palpation: Gentle pressure may reproduce pain over the kidney or ureter. Tenderness helps localize the problem to the urinary tract.

4. Edema assessment: Leg or facial swelling suggests declining kidney function and fluid retention from chronic disease or acute injury.

Manual/bedside tests

5. Costovertebral angle (CVA) tenderness test: Tapping over the back where the kidneys sit can trigger sharp pain in obstruction or infection.

6. Bladder scan (portable ultrasound) after voiding: A quick bedside measurement shows if urine remains in the bladder. High residual volume suggests obstruction lower down.

7. Urine dipstick at the bedside: A simple strip can detect blood, protein, leukocyte esterase, and nitrites. Blood supports stone passage; infection markers need urgent care.

8. Pain score and stone passage diary: Recording pain intensity and any passed “sand” or stones helps track attacks and response to treatment.

Laboratory and pathological tests

9. Urinalysis with microscopy: A lab professional looks at urine under a microscope. DHA crystals are typically round to ovoid with fine radial striations; many tiny crystals can carpet the field. Hematuria and inflammatory cells may be present.

10. Stone analysis by infrared spectroscopy or X-ray diffraction: If a stone is captured, specialized analysis confirms 2,8-DHA composition. This distinguishes DHA from uric acid, xanthine, cystine, or calcium stones.

11. APRT enzyme activity assay (erythrocytes): A blood test measures how well APRT converts adenine to AMP. Very low or absent activity supports the diagnosis in patients and helps screen relatives.

12. APRT gene testing (molecular analysis): DNA testing identifies mutations in the APRT gene. It confirms the autosomal recessive disorder and allows family counseling and newborn testing.

13. Serum creatinine and eGFR: These measure kidney filtration. A rising creatinine or falling eGFR shows kidney injury from recurrent crystals or obstruction.

14. Serum electrolytes and bicarbonate: Abnormal potassium, sodium, and acid-base status occur with acute or chronic kidney failure and guide urgent care.

15. 24-hour urine volume and chemistry: Total volume documents hydration; citrate, pH, and other inhibitors help tailor prevention. DHA itself is not routinely reported on standard stone panels, so specific assays may be requested.

16. Urinary purine profiling (HPLC/LC-MS): Specialized labs can measure adenine and 2,8-DHA directly in urine. High DHA confirms active overproduction and helps monitor response to therapy.

Electrodiagnostic tests

17. Electrocardiogram (ECG): Severe kidney failure can cause high potassium, which changes the ECG (peaked T waves, QRS widening). ECG guides urgent treatment in advanced cases.

18. Ambulatory blood pressure monitoring (ABPM): Repeated high readings confirm hypertension linked to chronic kidney disease. This guides medication to protect the kidneys.

Imaging tests

19. Renal and bladder ultrasound: First-line imaging. It shows echogenic foci (stones), acoustic shadowing, and hydronephrosis if there is blockage. It is safe in children and pregnancy.

20. Non-contrast helical CT (CT-KUB): The most sensitive test for stones. It detects small stones and the exact site of obstruction. DHA stones are often radiolucent on plain X-ray but visible on CT.

21. Plain abdominal X-ray (KUB): Many DHA stones do not show on X-ray, but the film can still help track stents, other calcifications, or mixed stones.

22. Doppler ultrasound of renal vessels: Assesses blood flow and the resistive index in obstructed or inflamed kidneys. Persistent high indices suggest parenchymal injury.

23. Dual-energy CT or advanced CT characterization (where available): Specialized CT can help distinguish stone types by attenuation patterns. This may support the DHA diagnosis when stone material is not available.

24. Imaging of a transplanted kidney (ultrasound ± CT): In transplant patients with rising creatinine, imaging looks for stones, hydronephrosis, or other structural causes of graft dysfunction.

Non-pharmacological treatments

(Focus: simple, practical actions. For readability, each item is concise yet complete.)

Hydration & urine flow 

1. High fluid intake plan: aim for urine that is pale-yellow all day; spread water across waking hours; add a glass before bed and at wake-up. Purpose: dilute urine so crystals cannot clump. Mechanism: raises urine volume and lowers crystal supersaturation. Benefits: fewer stone events, less pain, kidney protection. WJNU

2. Timed voiding & not “holding” urine: empty bladder regularly (e.g., every 2–3 hours). Purpose: reduce stasis. Mechanism: limits time crystals sit and aggregate. Benefits: lowers blockage risk.

3. Sick-day hydration protocol: during vomiting/fever/diarrhea, switch to oral rehydration (small sips frequently); seek IV fluids if unable to keep liquids. Purpose: prevent dehydration triggers. Benefits: prevents acute crystal showers.

Nutrition & lifestyle 

1. Low-purine diet: limit organ meats, certain fish (anchovies, sardines), yeast/brewer’s yeast; emphasize fruits, vegetables, whole grains, and moderate plant proteins. Purpose: reduce adenine load. Mechanism: lower purine intake → less adenine to convert into 2,8-DHA. Benefits: fewer stones. (Diet is supportive; medication is still required.) WJGnet

2. Moderate protein distribution: spread protein across meals, avoid “protein bomb” dinners. Purpose: avoid purine spikes. Benefits: steadier metabolite load.

3. Limit alcohol binges: alcohol can dehydrate and increase purine load (beer/yeast). Purpose: reduce risk flares. Benefits: fewer attacks.

4. Heat management: in hot weather or saunas, pre-hydrate and rehydrate; use shade/cooling. Purpose: avoid dehydration. Benefits: protects kidneys.

5. Physical activity (gentle walking, cycling) during stone-free periods: supports general renal health and weight control; avoid strenuous dehydration.

Physiotherapy & pain-relief body work (mind-body integrated):

1. Diaphragmatic breathing for colic: slow, deep breathing lowers pain perception, reduces muscle guarding. Purpose: comfort while awaiting medical care. Benefits: less anxiety/pain.

2. Heat therapy (warm packs) to flank: relaxes muscles and improves comfort during spasms (avoid if fever). Purpose: analgesia. Benefits: symptom relief.

3. Pelvic floor relaxation practice: short, daily sessions to reduce guarding during urination. Purpose: ease voiding discomfort. Benefits: better bladder emptying.

4. Graded mobility during recovery: short, frequent walks help gas movement and reduce stiffness after procedures.

5. Sleep hygiene: consistent sleep supports pain tolerance and recovery.

Education & self-management:

1. Medication literacy: know your XO inhibitor dose, timing, interactions, and what to do if you miss a dose. Purpose: adherence. Benefits: prevents recurrence. WJGnet

2. Crystal-aware symptom diary: note pain, urine appearance, fluids, diet, and triggers; bring to visits. Purpose: pattern spotting. Benefits: tailored prevention.

3. Family screening education: explain inheritance; relatives with unexplained stones/CKD should discuss APRT testing. Purpose: early diagnosis. Benefits: prevents kidney damage. Lippincott Journals

4. Sick-day rules card: small card listing when to seek IV fluids, when to call the clinic, and which meds to continue.

5. UTI early-warning plan: teach signs (fever, burning, frequency) and prompt care to avoid obstruction + infection.

Clinic-linked non-drug supports:

1. Dietitian-guided meal plans (low-purine, culturally appropriate). Purpose: practical adherence. Benefits: sustainable habits.

2. Hydration tech: phone reminders or smart bottle to hit daily urine volume targets.

3. Workplace hydration plan: pre-filled bottles; scheduled breaks; employer note if needed.

4. Travel kit: water bottle, oral rehydration salts, and summary letter for ER. Purpose: prevent travel-related flares.

5. Post-procedure rehab check-ins: nurse/physio reviews for safe return to activity, incision care (if PCNL/URS).

Mind-body care:

1. Brief cognitive strategies (reframing, pacing, relaxation audio) to manage anxiety during flares; reduces ER overuse and improves coping.

2. Peer/online support (rare-disease communities) for motivation and adherence (moderated groups recommended).

---

Drug treatments

Safety note: Doses must be individualized—especially in kidney disease, in children, during pregnancy, and with drug interactions. The drugs below include the core, disease-modifying therapy and common supportive medicines used in stone care.

1. Allopurinol (XO inhibitor; disease-modifying). Dose: often 5–10 mg/kg/day in children, up to 300 mg/day (higher as needed/tolerated; adjust in CKD). Timing: once daily. Purpose: prevent 2,8-DHA production. Mechanism: inhibits xanthine oxidoreductase so adenine is not converted into 2,8-DHA. Side effects: rash (rare severe), liver enzyme rise, cytopenias; dose-adjust in CKD and avoid interactions. WJNUOrpha

2. Febuxostat (XO inhibitor; disease-modifying). Dose: commonly 40–80 mg once daily (renal dose adjustment less often needed than allopurinol; monitor CV risks per labeling). Purpose/mechanism: same as above; studies suggest greater reduction of urinary DHA vs. allopurinol at standard doses. Side effects: liver enzyme rise, rare rash; consider CV history. PubMed

3. Acetaminophen (paracetamol) (analgesic). Dose: per label/weight; limit total daily dose; safe in CKD at adjusted doses. Purpose: pain control for renal colic. Mechanism: central analgesic. Side effects: liver toxicity with overdose.

4. Ibuprofen / Naproxen (NSAIDs). Dose: per label; short courses only. Purpose: reduce colic pain by lowering prostaglandin-mediated ureteral spasm. Mechanism: COX inhibition. Side effects: GI upset/bleeding; kidney perfusion reduction—avoid or limit in CKD and with dehydration.

5. Tamsulosin (α-blocker; medical expulsive therapy for distal ureteral stones). Dose: 0.4 mg nightly for a few weeks. Purpose: may aid passage of small distal stones. Mechanism: relaxes ureteral smooth muscle. Side effects: dizziness, ejaculatory changes.

6. Nifedipine (alternative MET agent). Dose: low-dose SR per clinician. Purpose: ureteral relaxation. Side effects: hypotension, flushing.

7. Ondansetron (antiemetic). Dose: per label. Purpose: control nausea/vomiting during colic. Mechanism: 5-HT3 blockade. Side effects: constipation, QT prolongation.

8. Opioid (e.g., morphine) (rescue analgesia). Dose: titrated; short courses only. Purpose: severe refractory colic. Side effects: sedation, constipation, dependence risk.

9. Antibiotic (e.g., ceftriaxone or culture-guided choice) when obstruction + infection suspected. Purpose: treat UTI/pyelonephritis. Side effects: drug-specific; stewardship essential.

10. Antispasmodic (e.g., hyoscine butylbromide). Purpose: adjunct for spasm pain. Side effects: dry mouth, blurred vision.

11. Topical lidocaine patch over flank for short-term analgesia in selected adults. Side effects: local irritation.

12. IV crystalloids (not a “drug” in the home sense, but a core therapy in ER): restores volume during severe colic/dehydration.

13. Proton-pump inhibitor when NSAIDs are required and GI risk is high. Purpose: ulcer prevention.

14. Bowel regimen (stool softener) if opioids used; prevents constipation and straining.

15. Avoid routine urine alkalinization (potassium citrate) as a “dissolver” for 2,8-DHA stones—the solubility of 2,8-DHA is not meaningfully improved by urine pH. Use only if another stone type coexists and your clinician advises it. WJNU

---

Dietary molecular / supportive supplements

(Always clear with your clinician; evidence targets kidney health and stone risk generally. For 2,8-DHA stones, medication remains essential.)

1. Citrus intake (lemons/limes): adds dietary citrate that may help broader stone risk profile; does not dissolve 2,8-DHA specifically.

2. Magnesium (e.g., magnesium citrate): may support general stone risk reduction; check dose in CKD.

3. Adequate dietary calcium with meals: binds oxalate in gut (general stone prevention principle); balance with CKD advice.

4. Potassium-rich foods (bananas, greens): support overall urinary health if potassium levels allow.

5. Fiber (soluble): supports metabolic health and weight control.

6. Omega-3 (fish oil): anti-inflammatory support; monitor bleeding risk.

7. Probiotics (general gut health); limited direct stone evidence.

8. Oral rehydration salts during illness to maintain volume.

9. Vitamin B6 (pyridoxine) – mixed evidence in stone literature; consider only if advised.

10. Avoid high-purine supplements (yeast/brewer’s yeast, certain organ extracts).

---

“Immunity booster / regenerative / stem-cell” drugs

There are no approved immune-booster, regenerative, or stem-cell drugs for APRT deficiency or 2,8-DHA stones. Management relies on XO inhibition (allopurinol/febuxostat) plus hydration and diet. Research ideas exist but remain experimental:

1. AAV-mediated APRT gene therapy: concept—deliver a working APRT gene to liver/kidney; not clinically available yet.

2. mRNA therapy for APRT: concept—temporary enzyme expression; investigational.

3. CRISPR-based editing: concept—fix APRT variants; ethical and safety hurdles remain.

4. Hepatocyte-targeted gene transfer: concept—restore purine salvage in liver to lower adenine load.

5. Enzyme replacement: concept—engineered APRT protein; not practical today.

6. Nephroprotective add-ons (e.g., SGLT2 inhibitors in appropriate CKD/diabetes patients): kidney-protective in general CKD, not disease-specific; discuss with a nephrologist.

---

Surgeries / procedures

1. Ureteroscopy (URS) with laser lithotripsy: a thin scope enters the ureter/kidney to break and remove stones. Why: for obstructing stones, infection with obstruction, or failed conservative care.

2. Percutaneous nephrolithotomy (PCNL): keyhole tract to the kidney to remove larger stones. Why: large burden or when URS/SWL are unsuitable; used successfully in reported 2,8-DHA cases. WJNU

3. Ureteral stent placement: small tube to bypass blockage and drain urine. Why: urgent relief of obstruction, especially with infection.

4. Percutaneous nephrostomy: drain placed through the back into the kidney. Why: emergency decompression when stent is not feasible.

5. Shock-wave lithotripsy (SWL): focused sound waves to fragment stones; localization can be challenging in radiolucent stones; effectiveness may vary. Why: selected small stones when visible and accessible. Uroweb

---

Prevention

1. Take allopurinol or febuxostat exactly as prescribed—lifelong unless your specialist says otherwise. WJGnet

2. Keep urine pale-yellow (high fluid intake spread through the day). WJNU

3. Follow a low-purine diet; limit organ meats/yeast-rich foods.

4. Plan extra fluids for heat, exercise, illness, or travel.

5. Act fast on UTI symptoms (burning, fever, urgency).

6. Keep a stone/crystal diary (symptoms, diet, fluids).

7. Attend regular nephrology/urology check-ups with labs and imaging as advised.

8. In families, consider screening and genetics discussions. Lippincott Journals

9. Avoid unnecessary NSAID overuse, especially if kidney function is reduced.

10. Carry a summary card: “APRT deficiency (2,8-DHA stones)—needs XO inhibitor.”

---

When to see a doctor

• Severe, unrelenting flank pain, fever, or chills with urinary symptoms (possible infection + obstruction – emergency).

• Unable to keep fluids down (risk of dehydration and crystal shower).

• Blood in urine, very low urine output, or swelling.

• New stone symptoms during pregnancy.

• After a kidney transplant, any drop in kidney function or flank pain. PMC

---

What to eat and what to avoid

1. Do: drink water regularly; add a glass at bedtime and upon waking.

2. Do: enjoy fruits/vegetables/whole grains; focus on varied plant foods.

3. Do: spread protein across meals; favor moderate amounts.

4. Do: use citrus (lemon/lime) in food or water for general stone risk reduction.

5. Do: use oral rehydration solutions during illness.

6. Avoid: organ meats, anchovies/sardines, yeast/brewer’s yeast supplements (high purine).

7. Avoid: alcohol binges; avoid dehydration.

8. Avoid: crash high-protein diets.

9. Be cautious: with over-the-counter supplements (check if purine-rich).

10. Follow: any CKD-specific diet advice from your nephrologist.

---

FAQs

1) Is this the same as uric-acid stones?
No. 2,8-DHA stones come from APRT deficiency, not uric acid metabolism alone. They often do not show on plain X-ray, but do show on ultrasound/CT. UK Kidney Association

2) Will alkalinizing my urine dissolve these stones?
No. 2,8-DHA solubility does not improve much with pH. Hydration and XO inhibitors are key. WJNU

3) What medicine prevents new stones?
Allopurinol or febuxostat (XO inhibitors) lower 2,8-DHA production. Lifelong therapy is recommended. WJGnet

4) Which is better: allopurinol or febuxostat?
Both work; in a small study, febuxostat lowered urinary DHA more than allopurinol at standard doses. Choice depends on age, kidney function, risks, and clinician judgment. PubMed

5) Can this cause kidney failure?
Yes—if untreated, repeated crystal injury can lead to CKD/ESKD. Early treatment prevents this. Lippincott Journals

6) Can it come back after kidney transplant?
Yes, if APRT deficiency is not recognized and treated; recurrence can harm the new kidney. PMC

7) How is the diagnosis confirmed?
Urine crystals + stone analysis + low APRT enzyme activity and/or APRT gene testing. PMC

8) Are the stones always invisible on X-ray?
Usually radiolucent, but rare radiopaque cases exist. Ultrasound/CT are preferred. PubMed

9) What does infant diaper staining mean?
Reddish-brown staining can be heavy crystalluria—see a pediatrician promptly. UK Kidney Association

10) Do I still need medication if I drink a lot of water?
Yes. Hydration helps, but XO inhibition is the cornerstone to stop 2,8-DHA formation. WJGnet

11) Should my relatives be tested?
Discuss family screening with your clinician, especially if relatives have early stones or unexplained CKD. Lippincott Journals

12) Can diet alone cure it?
No. Diet supports care but cannot replace XO inhibitors.

13) Are there approved gene or stem-cell cures?
No. Such approaches are experimental.

14) What follow-up do I need?
Regular labs (kidney function), urine checks, imaging as advised, and medication review.

15) What if I miss doses?
Take the dose when remembered (do not double up unless instructed). Call your clinic if you miss several doses; nonadherence raises relapse risk. WJGnet

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.